[Flunarizine in the treatment of arteriopathies of the legs].
Flunarizine, a long-acting calcium antagonist, was studied in patients with peripheral vascular disease in order to assess its effects on blood viscosity, erythrocyte deformability, platelet activity and some clinical parameters. A randomized double-blind study was performed; all patients were given a standard diet, invited to abstain from smoking and to carry out a regular daily exercise (walking). After a 2-month run-in period the patients were divided into two groups: one was treated with flunarizine 10 mg/day and the other with placebo. The group treated with flunarizine presented marked and significant reduction of erythrocyte filtration time and blood viscosity and an improvement of the treadmill-free interval with a correlation between the parameters considered.
D000368:Aged; D001809:Blood Viscosity / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002936:Cinnarizine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004311:Double-Blind Method; D004907:Erythrocyte Deformability / Q000187:drug effects; D005444:Flunarizine; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D012212:Rheology
D002121:Calcium Channel Blockers; D010879:Piperazines; D002936:Cinnarizine; D005444:Flunarizine
La flunarizina nel trattamento delle arteriopatie degli arti inferiori.